LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis. MET over-expression (with or without gene amplification), aberrant a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2012
Assuntos:
Preclinical Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717159/
https://ncbi.nlm.nih.gov/pubmed/23275061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9912-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados